| Autor: |
Duminuco A; Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy., Maugeri C; Division of Hematology, A.O.U. 'Policlinico G.Rodolico-S.Marco', 95123 Catania, Italy., Parisi M; Division of Hematology, A.O.U. 'Policlinico G.Rodolico-S.Marco', 95123 Catania, Italy., Mauro E; Division of Hematology, A.O.U. 'Policlinico G.Rodolico-S.Marco', 95123 Catania, Italy., Fiumara PF; Division of Hematology, A.O.U. 'Policlinico G.Rodolico-S.Marco', 95123 Catania, Italy., Randazzo V; Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy., Salemi D; Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy., Agueli C; Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy., Palumbo GA; Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy.; Division of Hematology, A.O.U. 'Policlinico G.Rodolico-S.Marco', 95123 Catania, Italy.; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy., Santoro A; Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy., Di Raimondo F; Division of Hematology, A.O.U. 'Policlinico G.Rodolico-S.Marco', 95123 Catania, Italy.; Department of Chirurgia Generale e Specialità Medico-Chirurgiche, University of Catania, 95123 Catania, Italy., Vetro C; Division of Hematology, A.O.U. 'Policlinico G.Rodolico-S.Marco', 95123 Catania, Italy. |
| Abstrakt: |
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase family member. Mutations in FLT3 , as well known, represent the most common genomic alteration in acute myeloid leukemia (AML), identified in approximately one-third of newly diagnosed adult patients. In recent years, this has represented an important therapeutic target. Drugs such as midostaurin, gilteritinib, and sorafenib, either alone in association with conventional chemotherapy, play a pivotal role in AML therapy with the mutated FLT3 gene. A current challenge lies in treating forms of AML with extramedullary localization. Here, we describe the general features of myeloid sarcoma and the ability of a targeted drug, i.e., gilteritinib, approved for relapsed or refractory disease, to induce remission of these extramedullary leukemic localizations in AML patients with FLT3 mutation, analyzing how in the literature, there is an important development of cases describing this promising potential for care. |
